Nadeem M, Sklover L, Sloane JA. Targeting remyelination treatment for multiple sclerosis. World J Neurol 2015; 5(1): 5-16 [DOI: 10.5316/wjn.v5.i1.5]
Corresponding Author of This Article
Jacob A Sloane, Director, Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Ks212, Boston, MA 02115, United States. jsloane@bidmc.harvard.edu
Research Domain of This Article
Neurosciences
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Neurol. Mar 28, 2015; 5(1): 5-16 Published online Mar 28, 2015. doi: 10.5316/wjn.v5.i1.5
Targeting remyelination treatment for multiple sclerosis
Maheen Nadeem, Lindsay Sklover, Jacob A Sloane
Maheen Nadeem, Lindsay Sklover, Jacob A Sloane, Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, Boston, MA 02115, United States
Author contributions: All authors contributed to this work.
Conflict-of-interest: There is no conflict of interest on the part of any author of this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jacob A Sloane, Director, Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Ks212, Boston, MA 02115, United States. jsloane@bidmc.harvard.edu
Telephone: +1-617-6673742 Fax: +1-617-6671869
Received: September 28, 2014 Peer-review started: September 29, 2014 First decision: October 21, 2014 Revised: December 9, 2014 Accepted: December 18, 2014 Article in press: December 19, 2014 Published online: March 28, 2015 Processing time: 236 Days and 17.2 Hours
Core Tip
Core tip: Over the last several years numerous remyelination pathways important to multiple sclerosis (MS) have been identified, including those of LINGO-1, hyaluronan, Notch-1, retinoid X receptor receptor, and wnt/ß-catenin. Newer discoveries include the pathways involving Chemokine (C-X-C Motif) ligand 12/C-X-C chemokine receptor type 4 and G protein-coupled receptor 17, and the involvement of Endothelin-1 in the Notch pathway. High-throughput screens have identified multiple antimuscarinic drugs with good remyelination. Also identified by screens, clemastine, with similar antimuscarinic but also antihistamine effects, may be useful in remyelination in MS. Drug repurposing, through screens or more serendipitously, has found that many drugs could enhance remyelination, including benztropine, clemastine, quetiapine, fasudil, olesoxime, and ibudilast, among others.
